APVO ▼ -0.6% - Aptevo Therapeutics Inc.
$APVO - Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
26-OCT-2026 08:05 AM ET
Share this post
More filings for $APVO
APVO ▼ -1.2% - Aptevo Therapeutics Inc.Oct 14, 2026APVO ▲ +4.5% - Aptevo Therapeutics Inc.Oct 12, 2026APVO ▲ +2.1% - Aptevo Therapeutics Inc.Sep 24, 2026APVO ▼ -12.7% - Aptevo Therapeutics Inc.Sep 3, 2026APVO ▲ +8.1% - Aptevo Therapeutics Inc.Sep 2, 2026APVO ▲ +8.1% - Aptevo Therapeutics Inc.Sep 2, 2026
View full $APVO filing history →💬 Comments
Loading comments…
Leave a comment